Boniva Injection
Generic Name:
Ibandronate
Brand Names:
Boniva, Boniva Tablet
Boniva Injection Description:
Boniva is a bisphosphonate medication used to prevent and treat osteoporosis, a condition in which the bones become thin or weak and may break easily. Boniva works to prevent the breakdown of bones and to increase bone density, particularly in postmenopausal women.
Boniva Injection Uses:
Boniva is used in the treatment of osteoporosis in postmenopausal women. Osteoporosis occurs when the bones become porous, causing them to become weak or brittle. People with osteoporosis do not have adequate bone gain to equal bone loss. Bone deterioration can lead to fractures or the deterioration of the spine, leaving the back unable to support weight (hunchback).
Boniva works by blocking the activity of bone breakdown and the release of calcium from bone into the blood. Boniva also helps to increase bone gain to counteract bone loss.
Boniva Injection Interactions:
Boniva may interact with H2 blockers, which may cause the bioavailability of Boniva to increase.
Bisphosphonates have been known to interfere with bone-imaging agents.
Side effects may be increased when Boniva is used in combination with cancer chemotherapy and oral steroids including:
- Dexamethasone (Decadron, Dexone)
- Methylprednisolone (Medrol)
- Prednisone (Deltasone)
Boniva Injection Dosage Information:
Typical Dosage Recommendation:
The Boniva injection is given intravenously by a healthcare professional every 3 months in the amount of 3 mg. The injection should be delivered from the pre-filled syringe over a period of 15 to 30 seconds. Do not mix the injection with any solutions that contain calcium or other intravenous drugs.
Missing a Dose:
If you miss a dose of injectable Boniva, have the injection as soon as you remember. Schedule all follow-up doses for the three months following your first injection. Do not take Boniva injections more frequently than every three months.
Overdosing:
The Boniva injection is provided by a medical professional every three months, so there should be little chance of overdose.
Boniva Injection FDA Approval:
January 6, 2006
Boniva Injection Recall/Black Box Warning Information:
There have been no recalls or Black Box warnings issued by the FDA for the Boniva injection.
Other Warnings:
The FDA has issued a warning regarding increased abnormal heart rhythm (atrial fibrillation) in patients using bisphosphonates such as Boniva.
Patients must receive calcium and vitamin D supplements while taking Boniva.
Treatment with intravenous bisphosphonates such as the Boniva injection has been linked to kidney (renal) toxicity and, in rare cases, kidney failure. The risk of serious kidney toxicity with bisphosphonates seems to be linked to the rate of drug administration. No cases of severe kidney failure were observed with Boniva during clinical trials where the drug was administered over 15 to 30 seconds. Boniva should not be administered to patients with severe kidney impairment.
Bone death (osteonecrosis), particularly in the jaw, has been associated with use of bisphosphonates. Most cases were in cancer patients who were undergoing dental procedures.
Acute, and sometimes debilitating, bone, joint and/or muscle pain has been observed in patients takings bisphosphonates such as Boniva. These occurrences are infrequent and most symptoms dissipated after cessation of treatment.
-
July 30, 2010, 2:23 pm
-
July 30, 2010, 2:13 pm
-
July 29, 2010, 12:33 pm
-
July 28, 2010, 3:58 pm
